Search results
Results from the Health.Zone Content Network
In May 2020, Australia's first human trials of a candidate COVID‑19 vaccine, Novavax's NVX-CoV2373, began in Melbourne. It involved about 130 volunteers aged between 18-59. Phase III. In September 2020, Novavax started for a phase III trial with 15,000 in the UK.
Vaccines such as the COVID-19 vaccine are inactivated virus vaccines. These vaccines don’t contain live viruses, and can’t transmit infections. That’s why there are no restrictions on blood ...
The health risks associated with getting COVID-19 far outweigh the risk of getting TTS from a vaccine. In addition to severe respiratory illness and other issues, blood clots are a potential side ...
In rare cases, shortness of breath can happen after the COVID-19 vaccine. This can be caused by rare adverse effects like myocarditis, pericarditis, or anaphylaxis. With treatment, many people ...
Blood donation is a simple act that can save lives. People may need blood when they have surgery, cancer treatment, or transfusions for blood loss from injuries or accidents.But only 3% of age ...
2 min read. Oct. 4, 2023 – The updated COVID-19 vaccine made by Novavax is now approved for use in the U.S., and millions of the doses are heading to pharmacies and other health care sites ...
The rapidly growing infection rate of COVID‑19 worldwide during 2020 stimulated international alliances and government efforts to urgently organize resources to make multiple vaccines on shortened timelines, with four vaccine candidates entering human evaluation in March (see the table of clinical trials started in 2020, below).
Federal mandates. In September 2021, Biden announced the Biden administration COVID-19 action plan, a six-point plan of new measures to help control the pandemic, which included new executive orders and regulatory actions to effectively mandate vaccination for COVID-19 among a large swath of the American workforce.